TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06300320: A Randomized, Open-label, Multicenter Phase II Clinical Trial of Rovadicitinib in the Treatment of Third-line and Subsequent Moderate to Severe Chronic Graft-versus-host Disease (cGVHD).

Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Phase: PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 65 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$6,108,800

Rescue Site Savings

+$4,017,200

Unlock Full NCT06300320 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06300320 Rescue Dossier →